Posted February 8, 2018
A highly concerning study published in the journal Diabetes, Obesity and Metabolism titled, “Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events, and incident cancer,” adds to a growing body of research indicating that administering genetically engineered insulin to type 2 diabetics greatly increases their risk of all-cause mortality. Read more.